U.S. Clears Way for Drugmakers to Share COVID Antibody Capacity - COVID-19 Clinical Trial
Breaking News | COVID-19

U.S. Clears Way for Drugmakers to Share COVID Antibody Capacity

The U.S. Department of Justice on Thursday said it will not stand in the way of efforts by companies, including Eli Lilly and Co and Amgen Inc, to share information to help scale up capacity to manufacture antibody treatments for COVID-19, the disease caused by the new coronavirus.

The drugmakers are in various stages of developing experimental monoclonal antibodies – manufactured proteins designed to bind to a targeted cell, neutralize it and mark it for destruction by the immune system – for treatment, or even prevention, of COVID-19. Monoclonal antibodies are among the most common type of biotech medicines, used for cancer, rheumatoid arthritis and many other conditions.


Moderna’s COVID-19 Vaccine Candidate Moves into Late-stage Trial

Moderna Inc said on Monday it has started a U.S. government-backed late-stage trial for its COVID-19 vaccine candidate, the first to be implemented under the Trump administration’s Operation Warp Speed anti-coronavirus program.

News of the study, which will test the response to the vaccine in 30,000 adults who do not have the respiratory illness, pushed shares in Cambridge, Massachusetts-based Moderna up 11% at $81.31 (63.3 pounds) before the bell.

The federal government is supporting Moderna’s vaccine project with nearly a billion dollars and has chosen it as one of the first to enter large-scale human trials.

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.